Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Primagen and OncoGenome link up on cancer tests:

This article was originally published in Clinica

Executive Summary

Dutch company Primagen is to design and develop multiple molecular cancer diagnostic tests for Liege, Belgian firm OncoGenome Sciences. Primagen will endeavour to design five genomics-based diagnostic tests that can detect cancer much earlier and more accurately than current tests, the Amsterdam firm says. The tests should also be able to predict and monitor response to therapy for optimal, more individualised treatment decisions. Commenting on the collaboration, OncoGenome's CEO Herman Spolders said: "We plan to start dedicated end-development of clinical diagnostic testing services and kits of the molecular tests designed by Primagen over a year, followed by clinical trials as the first activities in the FDA approval procedure." OncoGenome has recently completed a E12m ($12.8m) funding round (see Clinica No 1050, p 15).

You may also be interested in...

UK Biotech Financing Holds Up Despite Woodford and Brexit

Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector

Dr Reddy’s Focuses On India And China

Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.

Glenmark Sells Gynecology Unit

Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts